Glucose effects on the peritoneum: what can we learn from rodent models?

Area of Science:

• Nephrology
• Endocrinology
• Biochemistry

Background:

• Peritoneal dialysis (PD) solutions contain high glucose and metabolites, leading to peritoneal membrane damage and fibrosis over time.
• Advanced glycation end-products (AGEs) interacting with their receptors are key mechanisms driving peritoneal damage in both rodents and humans.
• PD-induced damage extends beyond the peritoneum, affecting systemic organs like the kidneys and cardiovascular system.

Purpose of the Study:

• To investigate the mechanisms of peritoneal membrane damage during long-term PD.
• To evaluate the efficacy of interventional strategies, such as benfotiamine (BF) and glyoxalase, in mitigating PD-induced damage.
• To assess the systemic effects of PD, particularly on renal and cardiovascular health.

Main Methods:

• Utilizing rodent models to study peritoneal damage and test interventions.
• Administering benfotiamine (BF), a vitamin B1 analogue, and glyoxalase as potential therapeutic agents.
• Monitoring structural and functional changes in the peritoneal membrane and assessing systemic organ damage.

Main Results:

• Long-term PD leads to peritoneal membrane reorganization and fibrosis, driven by glucose and AGEs.
• Benfotiamine intervention proved effective in preventing peritoneal damage and associated kidney damage.
• PD solutions contribute to both local peritoneal damage and systemic complications, highlighting a link to long-term diabetes.

Conclusions:

• Peritoneal dialysis can serve as a model for studying long-term diabetes complications.
• Benfotiamine demonstrates potential as a protective agent against PD-induced peritoneal and renal damage.
• Targeting AGEs and related pathways offers a strategy to mitigate the adverse effects of PD.